XJZY(SZ:002332) Xin Lang Cai Jing·2025-09-19 09:34Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has received a warning letter from the China Securities Regulatory Commission (CSRC) due to violations in the management and use of raised funds, which included improper procedures and mixing of funds [1][2]. Group 1: Regulatory Findings - The Zhejiang Securities Regulatory Bureau found multiple issues in the management of raised funds, including failure to follow proper review procedures for fund replacement and using raised funds for unrelated expenses [1]. - The company was also found to have mixed raised funds with its own funds when purchasing structured deposit financial products [1]. Group 2: Accountability and Measures - Key executives, including the Chairman, General Manager, CFO, and Board Secretary, were held primarily responsible for the violations and received warning letters [2]. - The company and its executives are required to enhance their understanding of relevant laws and regulations, improve financial management practices, and ensure accurate and timely information disclosure [2]. Group 3: Company Response - The company has expressed its commitment to addressing the issues raised in the warning letter and implementing stricter controls over the use of raised funds [2]. - It emphasized that the regulatory measures will not affect its normal production and operations, and it will continue to fulfill its disclosure obligations [2].